Log in
Enquire now
‌

US Patent 7582300 Modulation of gamma delta T cells to regulate airway hyperresponsiveness

Patent 7582300 was granted and assigned to National Jewish Health on September, 2009 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Current Assignee
National Jewish Health
National Jewish Health
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
7582300
Date of Patent
September 1, 2009
Patent Application Number
10808846
Date Filed
March 24, 2004
Patent Citations Received
‌
US Patent 12110328 Single domain antibodies targeting CD1d
0
‌
US Patent 11673952 Antibodies specific to delta 1 chain of T cell receptor
0
‌
US Patent 12077586 Bispecific antibodies for use in the treatment of hematological malignancies
0
‌
US Patent 12084500 Antibodies specific to delta 1 chain of T cell receptor
0
Patent Primary Examiner
‌
Maher M. Haddad
Patent abstract

Disclosed is a method for regulation of airway hyperresponsiveness by modulating the action of γδ T cells in a patient. Also disclosed are methods for identifying compounds that regulate airway hyperresponsiveness by modulating γδ T cell action.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7582300 Modulation of gamma delta T cells to regulate airway hyperresponsiveness

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.